To mark World Parkinson’s Day and underscore the importance of exercise for patients, the British fitness instructor known as “Mr. Motivator” is partnering with Parkinson’s UK. On April 13, the exercise guru will devote his weekly and half-hour, online Motivation Club class to Parkinson’s disease (PD), the organization announced.
A just-launched wellness program is offering a two-week, inpatient rehabilitation experience tailored to the needs of people with Parkinson’s disease. Its goal is to maximize patients’ independence. The program is being offered by the Hackensack Meridian JFK Johnson Rehabilitation Institute, in Edison, New Jersey. “In our new program, patients…
Markers of age in the retina — the layer of tissue at the back of the eyeball chiefly responsible for sensing light — can be used to predict the risk of future Parkinson’s disease, a new study indicates. The study, “Retinal age gap as a predictive…
The global advertising company Havas Creative has launched an application — called the Staybl app — that’s designed to make the use of digital devices easier for people, including Parkinson’s disease patients, who experience involuntary shaking known as tremors. The new Staybl app was developed in a collaboration…
Scientists have created a set of sensors that can help measure muscle strain and bulging while integrated in a wearable device, such as clothes, a feature that may be of use for people with Parkinson’s disease. The sensors could be used to remotely monitor disease progression, quantify the effects, and…
To mark the start of Parkinson’s Awareness Month, the Parkinson’s Foundation has kicked off its #FutureofPD Campaign, an initiative to call attention to the progressive neurodegenerative disorder and highlight what can be done to create a better future for the Parkinson’s disease community. “Parkinson’s disease affects nearly…
Using Cerevance’s oral CVN424 as an add-on therapy for Parkinson’s motor symptoms led to a significant and meaningful dose-dependent reduction in “off” time — periods when symptoms reappear or worsen — data from a Phase 2 study show. The trial also met its safety objectives, according to a…
Inhibikase expects to begin a Phase 2a study of IkT-148009, its investigational therapy for Parkinson’s disease, in the second quarter of 2022, with dosing of the first patient being subject to clearance by the U.S. Food and Drug Administration (FDA). Last year, the company began dosing IkT-148009…
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…
Azilect (rasagiline) as an add-on therapy to Requip (ropinrole) improved sleep, reduced the need for sleep medications, and enhanced quality of life in a small group of people with Parkinson’s disease, a study suggested. These findings support more extensive studies to confirm the sleep-related benefits of Azilect,…
Get regular updates to your inbox.
